Also known as: BNT323, IMDELLTRA
Imdelltra (tarlatamab-dlle) is a DLL3-directed bispecific T-cell engager immunotherapy for adults with extensive-stage small cell lung cancer after platinum-based chemotherapy progression. It first received FDA accelerated approval in 2024 and was converted to traditional full approval in November 2025. The treatment requires specialized step-up dosing and monitoring for cytokine release syndrome and neurologic toxicities.
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
